2022 annual financial data
Spyre Therapeutics 2022 Operating margin
Direct answer
Operating margin was -3,640.23%.
Operating income was -84,781,000 USD and net income was -83,815,000 USD.
Operating cash flow was -80,144,000 USD.
Get free Spyre Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 2,329,000 USD
- Operating income
- -84,781,000 USD
- Net income
- -83,815,000 USD
- Operating cash flow
- -80,144,000 USD